Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NMRA
stocks logo

NMRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.332
-10.17%
--
--
-0.317
-24.6%
--
--
-0.263
-20.2%
Estimates Revision
Stock Price
Go Up
up Image
+35.42%
In Past 3 Month
Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is 8.67 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is 8.67 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 2.275
sliders
Low
3.00
Averages
8.67
High
18.00
Current: 2.275
sliders
Low
3.00
Averages
8.67
High
18.00
Stifel
Hold
maintain
$2 -> $3
2025-11-17
Reason
Stifel
Price Target
$2 -> $3
2025-11-17
maintain
Hold
Reason
Stifel raised the firm's price target on Neumora Therapeutics to $3 from $2 and keeps a Hold rating on the shares following Q3 earnings and hosting management at the firm's annual Healthcare Conference. NMRA-511's Phase 1b readout in AD agitation is expected to readout by year-end and expectations are low despite favorable initial tolerability data, making this catalyst "arguably upside-skewed," the analyst tells investors.
Needham
Buy
maintain
$6 -> $8
2025-10-28
Reason
Needham
Price Target
$6 -> $8
2025-10-28
maintain
Buy
Reason
Needham raised the firm's price target on Neumora Therapeutics to $8 from $6 and keeps a Buy rating on the shares. The firm is more positive on Neumora following its R&D Investor Event which underscored its broad pipeline beyond navacaprant leveraging best in class pharmacology, and brain penetrant chemistry, targeting novel mechanisms with potential to improve current standard of care, the analyst tells investors in a research note.
Guggenheim
Neutral -> Buy
upgrade
$14
2025-10-27
Reason
Guggenheim
Price Target
$14
2025-10-27
upgrade
Neutral -> Buy
Reason
Guggenheim upgraded Neumora Therapeutics to Buy from Neutral with a $14 price target following the "compelling" preclinical obesity data reported by the company. The firm views the company's NLRP3i program in obesity and related disorders as "a clear driver to value creation," the analyst tells investors.
JPMorgan
Neutral -> Underweight
downgrade
2025-09-16
Reason
JPMorgan
Price Target
2025-09-16
downgrade
Neutral -> Underweight
Reason
JPMorgan downgraded Neumora Therapeutics to Underweight from Neutral without a price target. The company's Phase 3 KOASTAL-1 trial evaluating navacaprant as a monotherapy treatment in major depressive disorder failed to hit its primary endpoint or key secondary endpoint earlier this year, the analyst tells investors in a research note. The firm believes Neumora shares will continue to underperform peers into the Phase 3 KOASTAL-2 and KOASTAL-3 trial readouts.
Mizuho
Graig Suvannavejh
Outperform
maintain
$4 -> $5
2025-07-16
Reason
Mizuho
Graig Suvannavejh
Price Target
$4 -> $5
2025-07-16
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Neumora Therapeutics to $5 from $4 and keeps an Outperform rating on the shares following last week's introduction of NMRA-861. The firm projects a U.S. launch in 2034 and risk-unadjusted NMRA-861 sales of $1.2B in 2037. It sees a favorable risk/reward at current share levels.
Needham
Ami Fadia
Strong Buy
Reiterates
$5
2025-04-10
Reason
Needham
Ami Fadia
Price Target
$5
2025-04-10
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neumora Therapeutics Inc (NMRA.O) is -1.93, compared to its 5-year average forward P/E of -4.91. For a more detailed relative valuation and DCF analysis to assess Neumora Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.91
Current PE
-1.93
Overvalued PE
-1.27
Undervalued PE
-8.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.30
Undervalued EV/EBITDA
-7.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 327.95% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NMRA News & Events

Events Timeline

(ET)
2025-12-01
12:11:00
Major Averages Decline as Investors Await Economic Data and Powell's Speech
select
link
2025-11-12 (ET)
2025-11-12
08:14:01
LB Pharmaceuticals names Kaya Pai Panandiker as Chief Commercial Officer
select
2025-11-06 (ET)
2025-11-06
07:01:47
Neumora Therapeutics announces Q3 earnings per share of 35 cents, surpassing consensus estimate of 34 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-02Benzinga
Analyst Recognizes Potential in Neumora's Growing Obesity and Metabolic Portfolio

  • RBC Capital Markets Upgrade: Neumora Therapeutics, Inc. has been upgraded from Sector Perform to Outperform by RBC Capital Markets, with a price target increase from $4 to $7, reflecting the company's potential beyond neurology.

  • Pipeline Developments: Neumora is advancing its NMRA-215 obesity treatment, showing promising preclinical results, and plans to initiate a clinical program in early 2026, alongside ongoing studies for its M4 franchise targeting neuropsychiatric disorders.

  • Financial Outlook: The company has $171.5 million in cash and equivalents, which is expected to sustain operations through 2027, indicating a solid financial position for upcoming developments.

  • Market Potential: Analysts highlight the NLRP3 target as a significant opportunity in metabolic and obesity treatments, with Neumora positioned to capitalize on this emerging market, despite some caution regarding its later-stage neuro programs.

[object Object]
Preview
4.0
12-01SeekingAlpha
Neumora Receives Upgrade from RBC Capital Markets Due to Obesity and Parkinson's Drug Potential

  • RBC Capital Markets Upgrade: RBC Capital Markets has upgraded Neumora Therapeutics (NMRA) to outperform, raising its price target to $7 from $4, citing the company's promising pipeline beyond neurology that is not reflected in its current stock price.

  • NLRP3 Inhibitor Potential: Analyst Brian Abrahams emphasized the potential of NMRA-215, a preclinical NLRP3 inhibitor targeting obesity and Parkinson's disease, noting its promising preclinical signals and lack of major toxicity concerns.

  • Competitive Landscape: Other companies, such as Ventyx Biosciences and Nodthera Therapeutics, are also developing NLRP3 inhibitors for similar conditions, indicating a competitive environment in this therapeutic area.

  • Cautious Outlook on Neuropsychiatric Programs: While optimistic about NMRA-215, Abrahams expressed caution regarding Neumora's later-stage neuropsychiatric programs, suggesting that current valuations do not reflect potential successes in these areas.

[object Object]
Preview
4.0
12-01Benzinga
Chevron Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday

  • Analyst Upgrades: Several Wall Street analysts have upgraded their ratings on various companies, including Neumora Therapeutics, Old Dominion Freight Line, Toast Inc, Chevron Corp, and Spyre Therapeutics.

  • Neumora Therapeutics: RBC Capital upgraded Neumora Therapeutics from Sector Perform to Outperform, raising the price target from $4 to $7, while shares closed at $2.24.

  • Old Dominion Freight Line: BMO Capital upgraded Old Dominion Freight Line from Market Perform to Outperform, lowering the price target from $172 to $170, with shares closing at $135.29.

  • Chevron Corp and Others: HSBC upgraded Chevron from Hold to Buy with a price target increase from $166 to $169, and other companies like Toast and Spyre Therapeutics also received positive upgrades from analysts.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neumora Therapeutics Inc (NMRA) stock price today?

The current price of NMRA is 2.275 USD — it has increased 0.22 % in the last trading day.

arrow icon

What is Neumora Therapeutics Inc (NMRA)'s business?

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

arrow icon

What is the price predicton of NMRA Stock?

Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is 8.67 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neumora Therapeutics Inc (NMRA)'s revenue for the last quarter?

Neumora Therapeutics Inc revenue for the last quarter amounts to -52.70M USD, decreased -31.24 % YoY.

arrow icon

What is Neumora Therapeutics Inc (NMRA)'s earnings per share (EPS) for the last quarter?

Neumora Therapeutics Inc. EPS for the last quarter amounts to -46649000.00 USD, increased 39.32 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neumora Therapeutics Inc (NMRA)'s fundamentals?

The market is revising No Change the revenue expectations for NMRA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 35.42%.
arrow icon

How many employees does Neumora Therapeutics Inc (NMRA). have?

Neumora Therapeutics Inc (NMRA) has 110 emplpoyees as of December 05 2025.

arrow icon

What is Neumora Therapeutics Inc (NMRA) market cap?

Today NMRA has the market capitalization of 386.61M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free